F-Prime Capital

Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines using base editing technology to treat serious diseases.

Denali Therapeutics is focused on developing therapies for neurodegenerative diseases using their proprietary TransportVehicle™ platform.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development of innovative products for the treatment of rare and ultra-rare diseases.

Toast is a powerful POS system designed specifically for the restaurant industry, enhancing the guest experience through modern technology.

Flywire is a global payments company that specializes in providing payment solutions tailored for various industries, including education, travel, healthcare, and B2B.

Ironwood Pharmaceuticals is focused on developing innovative treatments for gastrointestinal (GI) health, with a strong emphasis on improving patient outcomes through advanced therapeutic solutions.

Insmed is a global biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with serious diseases. The company emphasizes a patient-first approach and is committed to advancing science sustainably and ethically.

Seyond is a global provider of high-performance LiDAR systems, specializing in applications for autonomous driving, intelligent transportation systems, robotics, and industrial automation.

Iora Health is a primary care practice focused on providing affordable, accessible, and enjoyable healthcare through a blend of human-centered design and technology. It serves Medicare patients with a value-based care model.

Blueprint Medicines is focused on developing innovative therapies for patients with mast cell disorders and solid tumors, utilizing a proven drug discovery platform and robust clinical development infrastructure.

Prime Medicine is focused on transforming the lives of patients with debilitating diseases through its Prime Editing technology, a next-generation gene editing approach that aims to correct genetic mutations at their precise locations in the genome.

Sana Biotechnology is focused on engineered cells as medicines, aiming to repair and control genes or replace missing or damaged cells to address the underlying causes of diseases.

Early-stage TechBio investor focused on platform companies, distinguished by a trademarked TechBio focus and an embedded Fellows program placing MDs, PhDs, and experts as an in-house scientific brain trust. The firm coined and trademarked the term "TechBio" to capture the rise of innovation where technology meets biology. They invest in data-driven life sciences companies that solve problems affecting everyday people from across the globe.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Invests in disruptive, technology-focused startups; established in 1999.

Digital health venture capital firm focused on companies enabling new care delivery models or more efficient therapeutic development.